Clinical efficacy of hepatic arterial infusion chemotherapy combined with immune plus targe-ted therapy for lung metastasis of advanced hepatocellular carcinoma
10.3760/cma.j.cn115610-20220831-00481
- VernacularTitle:肝动脉灌注化疗联合免疫靶向治疗晚期肝细胞癌肺转移的临床疗效
- Author:
Xiaowei YANG
1
;
Ming YANG
;
Riga SU
;
Zhaoyue WANG
;
Ying LIU
;
Zhizhong REN
;
Yuewei ZHANG
Author Information
1. 清华大学附属北京清华长庚医院肝胆介入科，北京 102218
- Keywords:
Liver neoplasms;
Atezolizumab;
Bevacizumab;
Hepatic arterial infusion chemotherapy;
Multidisciplinary team
- From:Chinese Journal of Digestive Surgery
2022;21(S1):10-14
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common tumors of primary hepatic carcinoma, and one of the major causes of cancer related deaths worldwide. HCC has high incidence and mortality, with limited treatment. The prevention and treatment of HCC faces great challenges. At present, interventional therapy combined with immune plus targeted therapy has a synergistic effect and a significant effect in prolonging the survival time of patients and controlling tumors, which brings a brand-new therapeutic hope to patients with advanced HCC. The authors report a case of advanced HCC with lung metastasis who underwent hepatic arterial infusion chemotherapy combined with immune plus targeted therapy, with a result of good clinical effect on tumor controlling in a short time.
